ѱ̿Ǿǰȸ ȳ 帳ϴ.
ѱǻ '2021 ǻ â Һó հ' Ͽ,
ִ е ٶϴ.
ѱǻ 2021-14ȣ
츮 ǻо â ȭ Ȱȭ Ͽ Ʒ 2021 ǻ â Һó հ Ͽ Ʒ Ͽ ûϿ ֽñ ٶϴ.
2021 2 15
ѱǻ
ǻо â ȭ Ƿ R&D Ȱ뵵
̿, Ƿ ǻ Ưȭ ұ ۷ι ȭ Ƿ Ÿ
ǻо â Һó ȸ ġ
() ǻо
(Ⱓ) 2021. 2 ~ 2021. 11
Ϻλ Ⱓ (λ RFP )
(о) ǻо â‧ȭ
ǻ (6 )
λ |
| Ը () |
Ⱓ |
ֱ ۷ι ȭ | ۷ι ؿ ܰ ֱ ؿ 㰡, ȭ ҿ | 16 / 5õ (ִ) | 21.3 ~ 21.11 |
ΰ Ȱ žళ ȫ | ΰ Ȱ žళ DB, ΰ žళ ÷ ³Ʈũ ΰ Ȱ žళ ȫ ʿ | 1 / 970鸸 | 21.3 ~ 21.11 |
Ƿ ǰ (Ƿ) | ְ(Ƿ) Ƿ ǰ ʿ ҿ ü 30% ̻() δ δ | 20 / 75鸸 ~ 200鸸 | 21.3 ~ 21.11 (Ǵ ~ 22.11) |
Ƿ ɰ | ְ() Ƿ ǰ ɰ ʿ ҿ ( 30鸸 ̳ ǰ ʿ ҿ * ְ ּ 30% ̻ δ Ī( Ǵ ) | 6 / 20鸸 | 21.4 ~ 21.11 |
Ƿ ǰ ȸ (Ƿ) ٱ | ְ(ȸ) (Ƿ) Ƿ ǰ ʿ ҿ 30% ̻ δ δ | 3 / 200鸸(ִ) | 21.3 ~ 21.11 |
Ƿ ܰ躰 غ | ˻, GMP, ӻ, 㰡 ܰ迡 ģ ݻ ʿ Ÿ * û ּ 30% ̻ δ δ( Ǵ ) | 10 / 20鸸 ̳ | 21.3 ~ 21.11 |
(2 )
λ |
| Ը () |
Ⱓ |
ȸ | , Ƿ TLO(H+TLO) ġ Ƿ, Ƿ о м ü Ǵ ȸ | 10 / 9.5鸸 | 21.2 ~ 21.11 |
K-濪 Ȱȭ | K-濪ǰ 並 â ҽþ ̷ K-濪ǰ ‧ Ǻ ڱ | 5 / 5(ִ) | 21.3 ~ 21.11 |
(6 )
λ |
| Ը () |
Ⱓ |
ǻ ġ | Ƿ TLO, , , (ġ) | 45 | 1~3 |
ǻ â ǰ | ǰ ۿ ʿ ڱ | 12 / 20鸸 | 2~6 |
ǻ Ư(IP-R&D) | ǻо R&D ڸ ش ϰ ȣ ִ Ư R&D (ִ 45鸸 ̳) | 16 / 45鸸(ִ) | 3~6 |
ǻ ȭ (ǰȭ-㰡) | ǻ о ǰȭ Ǵ 㰡 ȭ ȹ ܰ Ͽ ()ǰ ȭ | 13 / 30鸸(ִ) | 3~6 |
â | â ȭ 繫 , ȭ , ġ(ǥ), ǻâ : | - | (1 ) |
ؿ GPKOL | Ʈ ¶ ڹ(GPKOL, Global Pharma Key Opinion Leader)* ¶ * 20 Ʈũ | - | - |
ұó âŰ (âڴ), âŰ (â 37̳ )
λ ǻ ڿ
[÷](2)
1. [] 2021 ǻ â Һó հ.pdf
2. [ 1] 2021 ǻ â Һó û.hwp
ش ѱǻ Ȩ(www.khidi.or.kr) ȮϽ ֽϴ. [Link]